拷贝数变异风险评分与青少年认知、精神病理及脑结构的关联
该研究基于费城神经发育队列社区样本,分析拷贝数变异(CNV)风险评分、多基因评分(PGS)与环境因素如何联合关联青少年认知与精神病理。结果显示,CNV风险评分升高与认知测试总准确率降低、精神病理及精神病谱系症状增加、脑体积偏离规范发育模型增大相关;联合PGS与环境因素可显著改善发育结局的统计模型。
要点
- CNV风险评分升高与认知测试总准确率降低相关(标准化β=0.12;95%CI 0.10-0.14;P=7.41×10-26)。
- CNV风险评分升高与总体精神病理及精神病谱系症状增加相关。
- CNV风险评分升高与脑体积偏离规范发育模型增大相关,联合PGS与环境因素可显著改善模型。
核心结论
- CNV风险评分升高与青少年较低认知能力、较高精神病理(含精神病谱系症状)及脑发育偏离规范MRI模型增大相关。
研究设计与样本
- 费城神经发育队列为社区基础研究,2009年11月5日至2011年12月30日经费城儿童医院儿科网络招募稳定健康且英语流利的参与者。
- 共纳入9498名8至21岁青少年,女性4906名(51.7%),平均(SD)年龄14.2(3.7)岁。
- 暴露包括基于负荷、预测不耐受和基因剂量敏感性模型衍生的CNV风险评分、全基因组关联研究衍生的PGS及环境因素(创伤暴露和社区社会经济地位)。
- 结局包括Penn计算机化神经认知测验评估的神经认知、基于学龄儿童情感障碍与精神分裂症量表结构化访谈评估的精神病理及磁共振成像评估的脑体积。
主要发现
- CNV风险评分升高与认知测试总准确率降低相关(标准化β=0.12;95%CI 0.10-0.14;P=7.41×10-26)。
- CNV风险评分升高与多个认知子领域准确率降低相关。
- CNV风险评分升高与总体精神病理增加及精神病谱系症状增加相关。
- CNV风险评分升高与脑体积偏离规范发育模型增大相关。
- CNV风险评分联合PGS与环境因素时,发育结局的统计模型显著改善。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Psychiatric and cognitive phenotypes have been associated with a range of specific, rare copy number variants (CNVs). Moreover, IQ is strongly associated with CNV risk scores that model the predicted risk of CNVs across the genome. But the utility of CNV risk scores for psychiatric phenotypes has been sparsely examined. OBJECTIVE: To determine how CNV risk scores, common genetic variation indexed by polygenic scores (PGSs), and environmental factors combine to associate with cognition and psychopathology in a community sample. DESIGN, SETTING, AND PARTICIPANTS: The Philadelphia Neurodevelopmental Cohort is a community-based study examining genetics, psychopathology, neurocognition, and neuroimaging. Participants were recruited through the Children's Hospital of Philadelphia pediatric network. Participants with stable health and fluency in English underwent genotypic and phenotypic characterization from November 5, 2009, through December 30, 2011. Data were analyzed from January 1 through July 30, 2021. EXPOSURES: The study examined (1) CNV risk scores derived from models of burden, predicted intolerance, and gene dosage sensitivity; (2) PGSs from genomewide association studies related to developmental outcomes; and (3) environmental factors, including trauma exposure and neighborhood socioeconomic status. MAIN OUTCOMES AND MEASURES: The study examined (1) neurocognition, with the Penn Computerized Neurocognitive Battery; (2) psychopathology, with structured interviews based on the Schedule for Affective Disorders and Schizophrenia for School-Age Children; and (3) brain volume, with magnetic resonance imaging. RESULTS: Participants included 9498 youths aged 8 to 21 years; 4906 (51.7%) were female, and the mean (SD) age was 14.2 (3.7) years. After quality control, 18 185 total CNVs greater than 50 kilobases (10 517 deletions and 7668 duplications) were identified in 7101 unrelated participants genotyped on Illumina arrays. In these participants, elevated CNV risk scores were associated with lower overall accuracy on cognitive tests (standardized β = 0.12; 95% CI, 0.10-0.14; P = 7.41 × 10-26); lower accuracy across a range of cognitive subdomains; increased overall psychopathology; increased psychosis-spectrum symptoms; and higher deviation from a normative developmental model of brain volume. Statistical models of developmental outcomes were significantly improved when CNV risk scores were combined with PGSs and environmental factors. CONCLUSIONS AND RELEVANCE: In this study, elevated CNV risk scores were associated with lower cognitive ability, higher psychopathology including psychosis-spectrum symptoms, and greater deviations from normative magnetic resonance imaging models of brain development. Together, these results represent a step toward synthesizing rare genetic, common genetic, and environmental factors to understand clinically relevant outcomes in youth.
引用
- Alexander-Bloch A, Huguet G, Schultz LM, et al. Copy Number Variant Risk Scores Associated With Cognition, Psychopathology, and Brain Structure in Youths in the Philadelphia Neurodevelopmental Cohort. JAMA Psychiatry. 2022. PMID: 35544191. doi:10.1001/jamapsychiatry.2022.1017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。